Floatz logo

AVEXITIDE

Glucose Metabolism Disorders

University Hospital, Gentofte, Copenhagenprotein_peptideN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Glucose Metabolism Disorders cohort.

Asset / SponsorPhaseRating
Metformin
SINA Health Education and Welfare Trust
Phase 4BBB
ZIDOVUDINE
Kirby Institute
Phase 4BB
Empagliflozin
SINA Health Education and Welfare Trust
Phase 4BB
Exenatide
RenJi Hospital
Phase 4BB
Glargine
Federico II University
Phase 4BB

View all 28 →

Same molecule, other indications

AVEXITIDE is also rated in:

prediabetes syndromeDormant
BB
Indicative ·
68 / 100
View asset →
obesity disorderDormant
B
Indicative ·
56 / 100
View asset →
hyperinsulinemic hypoglycemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →